**Bhopal (Madhya Pradesh): Authorities Ban Two More Syrups Following Coldriff Controversy**
In the aftermath of the Coldriff syrup tragedy, which claimed the lives of at least 16 children in Chhindwara and Betul, health authorities have intensified their scrutiny of similar medicinal syrups. Random checks revealed that two additional syrups failed quality tests and have been immediately banned for being of Non Standard Quality (NSQ).
The first substandard syrup identified is Ambroxol HCL, Guaiphenesine, Terbutaline Sulphate, and Menthol Syrup (Batch LSL25160, Mfg Jan 2025, Exp Dec 2026), manufactured by Shape Pharma Pvt Ltd, Surendranagar, Rajkot, Gujarat. Laboratory analysis detected 0.616% Diethylene Glycol (DEG) in this product.
The second is Bromohexin Hydrochloride, Terbutaline Sulphate, Guaiphenesine, and Menthol Syrup (Batch RO1GL2523, Mfg Jan 1, 2025), produced by Rednonex Pharmaceuticals Pvt Ltd, Bavla, Ahmedabad. This syrup was found to contain 1.342% DEG.
Following these findings, health authorities have initiated the seizure of stocks of both syrups. Reports indicate that one of the manufacturers had approximately 100 bottles stored in Indore. The Gujarat Drug Controller has also been notified to take further action.
**Background on the Coldriff Syrup Case**
Officials have revealed that the toxic Coldriff syrup had been circulating in the market for 10 to 15 years before its hazardous composition was identified. This syrup has now been confirmed as the cause behind the recent deaths of children due to poisoning.
Further investigations highlighted that the syrup should not have been prescribed to children under the age of four. However, doctor Praveen Soni reportedly prescribed it to young patients, contributing to the tragedy.
Health authorities continue to monitor the situation closely to prevent further incidents and safeguard public health.
*— Story by Staff Reporter*
https://www.freepressjournal.in/bhopal/mp-cough-syrup-case-two-more-syrups-fail-quality-test-after-coldrif-banned
